Stocks / Pfizer Inc. (NYSE: PFE) / NYSE:PFE (Pfizer Inc.)About PFEA research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra. Summary Profile Price History Financials Peer Comparison Share Info Performance Dividends Events Pfizer Inc. (NYSE: PFE) Latest News Investing Articles Down 50% with a 6.5% yield, is this massive S&P 500 stock a screaming buy? 14 December, 2024 | Mark Hartley Our writer considers the prospects of a once-massive S&P 500 stock that's fallen out of favour and now has a… Read more » Investing Articles 2 shares for value investors to consider buying 4 September, 2024 | Stephen Wright Investors looking for value shares might want to consider 3i and Pfizer as stocks that aren’t getting the attention they… Read more » Investing Articles 2 quality income shares that are on sale right now 3 August, 2024 | Stephen Wright Buying quality shares at discount prices is the way to generate a lasting passive income. So where are the opportunities… Read more » Investing Articles The falling Croda International share price is getting difficult to ignore 30 July, 2024 | Stephen Wright The Croda International share price is at its lowest level since 2017. It’s a quality business, but is this a… Read more » Investing Articles 2 dividend growth shares I’ve just bought for my Stocks and Shares ISA 17 April, 2024 | Stephen Wright Stephen Wright's been looking beyond the UK for dividend shares in the last couple of weeks. Here are the opportunities… Read more » Investing Articles £10,000 in savings? I’d buy these 2 dividend shares to hold for a decade of passive income 3 March, 2024 | Stephen Wright Stephen Wright thinks dividend shares are unbeatable for income investors. He has a UK drinks firm and a US pharma… Read more » Investing Articles With £1,000, I’d buy 45 shares of this unloved dividend stock for a passive income boost 25 February, 2024 | Stephen Wright Despite falling vaccine sales, Stephen Wright thinks there’s a great passive income opportunity with Pfizer shares below pre-pandemic levels. Read more » Investing Articles 3 healthcare dividend stocks to consider for passive income in 2024 7 January, 2024 | Ben McPoland Our writer takes a look at three dividend stocks from the US and UK that could provide attractive passive income… Read more » Investing Articles A 6% yield but down 48%! Is this value stock now too cheap to ignore? 23 December, 2023 | Stephen Wright As demand for Covid-19 vaccines wears off in 2023, Pfizer shares are down 48%. Stephen Wright thinks the stock looks… Read more » Investing Articles 3 reasons why Pfizer (NYSE:PFE) might be a great buy 10 June, 2022 | Stephen Wright Pfizer stock has struggled this year, while other pharmaceutical companies have done well. Should our author be looking at buying… Read more » Investing Articles 3 US stocks to buy for 2022 23 December, 2021 | Rupert Hargreaves These could be some of the best US stocks to buy for 2022 and beyond, says Rupert Hargreaves, who would… Read more » Investing Articles As Pfizer shares surge, should I buy the stock now? 9 November, 2021 | Rupert Hargreaves This Fool explains why he thinks Pfizer shares remain incredibly attractive at current levels, despite their recent performance. Read more » 12❯
Investing Articles Down 50% with a 6.5% yield, is this massive S&P 500 stock a screaming buy? 14 December, 2024 | Mark Hartley Our writer considers the prospects of a once-massive S&P 500 stock that's fallen out of favour and now has a… Read more »
Investing Articles 2 shares for value investors to consider buying 4 September, 2024 | Stephen Wright Investors looking for value shares might want to consider 3i and Pfizer as stocks that aren’t getting the attention they… Read more »
Investing Articles 2 quality income shares that are on sale right now 3 August, 2024 | Stephen Wright Buying quality shares at discount prices is the way to generate a lasting passive income. So where are the opportunities… Read more »
Investing Articles The falling Croda International share price is getting difficult to ignore 30 July, 2024 | Stephen Wright The Croda International share price is at its lowest level since 2017. It’s a quality business, but is this a… Read more »
Investing Articles 2 dividend growth shares I’ve just bought for my Stocks and Shares ISA 17 April, 2024 | Stephen Wright Stephen Wright's been looking beyond the UK for dividend shares in the last couple of weeks. Here are the opportunities… Read more »
Investing Articles £10,000 in savings? I’d buy these 2 dividend shares to hold for a decade of passive income 3 March, 2024 | Stephen Wright Stephen Wright thinks dividend shares are unbeatable for income investors. He has a UK drinks firm and a US pharma… Read more »
Investing Articles With £1,000, I’d buy 45 shares of this unloved dividend stock for a passive income boost 25 February, 2024 | Stephen Wright Despite falling vaccine sales, Stephen Wright thinks there’s a great passive income opportunity with Pfizer shares below pre-pandemic levels. Read more »
Investing Articles 3 healthcare dividend stocks to consider for passive income in 2024 7 January, 2024 | Ben McPoland Our writer takes a look at three dividend stocks from the US and UK that could provide attractive passive income… Read more »
Investing Articles A 6% yield but down 48%! Is this value stock now too cheap to ignore? 23 December, 2023 | Stephen Wright As demand for Covid-19 vaccines wears off in 2023, Pfizer shares are down 48%. Stephen Wright thinks the stock looks… Read more »
Investing Articles 3 reasons why Pfizer (NYSE:PFE) might be a great buy 10 June, 2022 | Stephen Wright Pfizer stock has struggled this year, while other pharmaceutical companies have done well. Should our author be looking at buying… Read more »
Investing Articles 3 US stocks to buy for 2022 23 December, 2021 | Rupert Hargreaves These could be some of the best US stocks to buy for 2022 and beyond, says Rupert Hargreaves, who would… Read more »
Investing Articles As Pfizer shares surge, should I buy the stock now? 9 November, 2021 | Rupert Hargreaves This Fool explains why he thinks Pfizer shares remain incredibly attractive at current levels, despite their recent performance. Read more »